New research from the Cantor Lab uncovers a targetable vulnerability in BRCA1-deficient cells, revealing a potential therapeutic opportunity for inherited breast cancers.
Richard Gregory, PhD (center), joined by Dean Terrence R. Flotte, MD (left), and Chancellor Michael F. Collins, MD (right), at the investiture ceremony on September 11, 2025.
Conducting collaborative, cutting-edge research to unravel molecular, cellular and genetic mechanisms of disease and translate our discoveries into innovative therapeutic strategies
Research
Explore how our bold discoveries are redefining our understanding of how diseases start and can be treated.
Education
Find out how MCCB equips students and early-career researchers with the skills and knowledge to drive scientific discovery.
Support
Learn more about how you can support MCCB’s fundraising initiatives to advance research at UMass Chan.
MCCB Recognitions & Achievements
Highlights from UMass Chan News
Getting Results…
UMass Chan leads new $4.4 million study to study melanoma
UMass Chan Medical School received a five-year, $4.4 million National Cancer Institute grant to study how transfer RNAs may fuel the spread of melanoma.
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Cancer Center, Faculty, Research, Cancer, Melanoma, Molecular, Cell and Cancer Biology, RNA, Latest News, Top Stories, Richard Gregory,
Recent Publications
Chowdhury et al. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Article | Ruscetti Lab
Conti et al. Dynamic phosphorylation of Hcm1 promotes fitness in chronic stress. Article | Benanti Lab
Peng et al. RAD51 is chromatin enriched and targetable in BRCA1-deficient cells. Article | Cantor Lab
Ramirez-Moya et al. The tRNA editing complex ADAT2/3 promotes cancer cell growth and codon-biased mRNA translation. Article | Gregory Lab
Jeffries et al. Single-cell transcriptomics and genomic changes in the ageing human brain. Nature, 2025. Article | Lodato Lab